What is Novilytic?
Novilytic is a molecular recognition company that leverages advanced nanotechnology to provide sophisticated monitoring solutions for the quality of lifesaving medicines. By employing cutting-edge molecular detection techniques, Novilytic aims to enhance the safety and efficacy of pharmaceutical products, addressing a crucial need within the healthcare industry. The company's innovative approach is designed to ensure that medicines meet stringent quality standards throughout their lifecycle.
How much funding has Novilytic raised?
Novilytic has raised a total of $1.7M across 2 funding rounds:
Debt
$54K
Angel/Seed
$1.6M
Debt (2021): $54K with participation from PPP
Angel/Seed (2022): $1.6M led by Elevate Ventures and Purdue Foundry
Key Investors in Novilytic
Elevate Ventures
Elevate Ventures is an active participant in shaping the future of Indiana by investing in cross-sector innovation-driven companies at Pre-Seed, Seed, and Series A stages. They provide funding and guidance for entrepreneurs and seek founders with grit, creativity, and coachability. Elevate Ventures sources founders with great ideas, validates pain points, and provides initial guidance to obtain capital.
Purdue Foundry
Purdue Foundry is an organization focused on supporting and accelerating innovation and entrepreneurship, often investing in early-stage companies with strong technological foundations.
PPP
Public-Private Partnership
What's next for Novilytic?
The recent major strategic investment signals Novilytic's transition into a significant growth phase, likely focused on scaling its operations, expanding its market reach, and further developing its proprietary nanotechnology platform. This enterprise-level funding will empower the company to accelerate its go-to-market strategy and solidify its position as a leader in pharmaceutical quality assurance. Future developments may include strategic partnerships and broader adoption of its monitoring solutions across the pharmaceutical sector.
See full Novilytic company page
